Page 2 - Ted Kummert News Today : Breaking News, Live Updates & Top Stories | Vimarsana

UiPath is one of the preeminent RPA platforms, helping to automate repetitive software-based tasks. It just acquired NLP startup Re:infer.

UiPath (NASDAQ:PATH – Get Rating) had its target price reduced by Needham & Company LLC from $85.00 to $40.00 in a research note released on Thursday morning, The Fly reports. They currently have a buy rating on the healthcare company’s stock. PATH has been the subject of a number of other research reports. Morgan Stanley […]

UiPath (NASDAQ:PATH – Get Rating) had its target price cut by Credit Suisse Group from $75.00 to $57.50 in a research report report published on Thursday morning, The Fly reports. They currently have an outperform rating on the healthcare company’s stock. A number of other analysts have also issued reports on PATH. Morgan Stanley raised […]

UiPath (NASDAQ:PATH – Get Rating) had its price target lowered by investment analysts at Canaccord Genuity Group from $55.00 to $30.00 in a report released on Thursday, Benzinga reports. The firm presently has a “hold” rating on the healthcare company’s stock. Canaccord Genuity Group’s price objective points to a potential upside of 27.33% from the […]

Signaturefd LLC raised its position in shares of UiPath Inc. (NASDAQ:PATH – Get Rating) by 564.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,560 shares of the healthcare company’s stock after buying an additional 3,024 shares during the quarter. Signaturefd LLC’s […]